描述 |
CNV1014802(GSK-1014802)是钠离子通道Nav1.7有效抑制剂。 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
相关类别 |
|
||||||||||||
溶解度 |
体外:
DMSO:83 mg / mL(264.04 mM;需要超声波和加热)
|
||||||||||||
储备液 |
|
||||||||||||
存储 |
|
||||||||||||
运输 |
室温;可能会有所不同 |
||||||||||||
SMILES |
O=C([C@H]1N[C@@H](C2=CC=C(OCC3=CC=CC=C3F)C=C2)CC1)N |
||||||||||||
参考文献 |
|
||||||||||||
相关活性 小分子 |
5-(N-乙基-N-异丙基)阿米洛利 | 利鲁唑 | (20s)人参皂苷 Rg3 | 卡立泊来德 | 盐酸Eleclazine | GS967 | Tenapanor | 氨苯蝶啶 | 盐酸雷诺嗪 | PF 05089771 | 醋酸氟卡胺 | 5-(4-氯苯基)-N-(3,5-二甲氧基苯基)-2-呋喃甲酰胺 | 盐酸Raxatrigine | 唑尼沙胺 | 辛可卡因 |
分子式 | C18H19FN2O2 |
---|---|
分子量 | 314.35400 |
精确质量 | 314.14300 |
PSA | 65.34000 |
LogP | 4.16160 |
~%
Raxatrigine
934240-30-9
|
文献:GLAXO GROUP LIMITED Patent: WO2007/42239 A1, 2007 ; Location in patent: Page/Page column 43-44 ; WO 2007/042239 A1 |
~%
Raxatrigine
934240-30-9
|
文献:CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
~%
Raxatrigine
934240-30-9
|
文献:CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
~%
Raxatrigine
934240-30-9
|
文献:CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
~%
Raxatrigine
934240-30-9
|
文献:CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
~%
Raxatrigine
934240-30-9
|
文献:CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
~%
Raxatrigine
934240-30-9
|
文献:CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
CNV1014802 |